Dineshbhurani

Dr Dinesh Bhurani

[Dineshbhurani @dbhurani]

@VincentRK I would like to combine good of both regimens. We have reasonable experience with FLAG-VEN with very high CRc rates and lower mortality. Our data are compared with Paradigm cohort

[andi roy @andiroy]

Great to see this out. What a wonderful effort from all involved!

[Vincent Rajkumar @VincentRK]

Chairs @ALLIANCE_org @SWOG @EAONC myeloma committees.
IMWG meeting.

@szusmani @DoctorAKrishnan @VincentRK

[Blood Cancers Today @Blood_Cancers]

Linvoseltamab yielded impressive response performance in patients with relapsed or refractory systemic light chain #amyloidosis, according to the LINKER-AL2 trial presented at #ASCO26.

📰 Read here: https://t.co/YHs5D1OSvb

[Elon Musk @elonmusk]

India’s birth rate has fallen below replacement.

Among those most educated, India’s birth rate fell below replacement many years ago.

[Carmelo Gurnari @CarmeloGurnari]

Podcast link https://t.co/4iKanqftmt

[Pallawi Torka @PallawiTorkaMD]

A compilation of top lymphoma/CLL abstracts from #EHA2026 by @lymphomahub steering committee.

Looking forward to some great data.
@chanyooncheah @Dr_KatLewis @tobyeyre82 @WomenInLymphoma @KrishPatelMD @elizabeth_budde @StefanoLuminari

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

#CMLsm #leusm

[Pallawi Torka @PallawiTorkaMD]

📢#lymsm Get all your CLL and BTK inhibitor questions answered in this upcoming @lymphomahub seminar with expert from both sides of the pond.

Link to register: https://t.co/yv7sI9nQen

[Sridhar Vembu @svembu]

vTitan medical equipment update: we have been shipping steadily and a big shipment of syringe pumps is getting ready at the factory!

We also have an affordable pump for Thalassemia (vTitan AccuFlow Thala pump) and over a thousand patients have benefited from it.

Our R&D team is working hard on many more products. Our particular focus is on affordability.

vTitan is teaching us a lot about hardware design and manufacturing.

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Delighted to share our new publication. Led by @doctorpemm & Dr @kristenpettitmd | examining the often hidden burdens for patients with PV #phlebotomies #MPNSM | @peter_mpn @PVReporter @MPN_Hub @GMPNAN @gmpnsf @mpn_consortium @MPN_RF @MpncoD

https://t.co/WvFVC0OCvY

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai89]

🎉 Out now in @ASTCT_Journal 🙌🏽

We need to really define "reduced dose" PTCy!

https://t.co/56Dz6027ir

[Binaytara @binaytara]

💰$250K+ USD in research awards (multiple $50K prizes). For hematology researchers worldwide. Get your hematology research reviewed by @NitinJainMD

[Cristiane D Bergerot, PhD, FASCO @crisbergerot]

Always wonderful to see @neerajaiims at #ASCO26! @PauloBergerot @ASCO

Congratulations on a fantastic presentation and on the @NEJM publication

[Vivek Subbiah, MD @VivekSubbiah]

🚨⭐️Wow! What a surprise!
⭐️Deeply honored to receive the Indo-American-Cancer-Association Award at @ASCO #ASCO26 for Outstanding Contributions to Drug Development & Pioneering Advances in Clinical Cancer Research 2026
👉This recognition means so much not just as a personal milestone, but as a reflection of the incredible VILLAGE that makes this work possible
🙏 Mentors who shaped MY thinking + collaborators who challenged & inspired me + Patients who trusted me with their care + friends & family who anchored me through it all
🙏Thank you to the IACA @IACAconnect leadership for this honor @DrSwami_Iyer @Santchawla1 Vinay Jain @jamecancerdoc @BrainTumorDoc @SewantiLimaye #PrecisionOncology🙏 #ASCO26 #IACA #DrugDevelopment #CancerResearch @OncoAlert @oncodaily @OpenMedicineHQ

[Naveen Pemmaraju, MD @doctorpemm]

I am honored to have led this effort🙏 @Daver_Leukemia for his amazing co-leadership🙏 @UTMDAnderson for the wonderful support to me & our #BPDCN team,patients,families&caregivers. Special 🙏 @ppisters @garciamanero @ChrisRFlowersMD @ACKoongMDPhD @DrHKantarjian for their support!

[Suzanne Lentzsch, MD, PhD @SLentzsch]

One of the most rewarding and emotional moments of my career took place at #ASCO2026. In 2015, I started the first-in-human trial of 11-1F4 (now anselamimab), supported by a small FDA grant and @columbiacancer. At the time, the path forward was far from certain. We faced limited funding, strong competition from Prothena’s NEOD001 program, and considerable skepticism from industry given the rarity of AL amyloidosis and the fact that competing programs were already much further advanced in development.

Despite these challenges, we continued to move forward step by step. The phase 1 study demonstrated encouraging results, ultimately leading to the founding and funding of Caelum Biosciences in 2017 and the launch of the subsequent phase 2 and phase 3 studies. Those efforts were later advanced and completed through the commitment and resources of @AlexionCARES and @AstraZenecaUS.

@ASCO I had the privilege of chairing the session when the final phase 3 results where presented by Dr. Wechalekar, which demonstrated a significant overall survival benefit in patients with stage IIIA/IIIB κ AL amyloidosis🙌. Seeing a scientific concept evolve from an investigator-initiated first-in-human study into a positive phase 3 trial is extraordinarily rewarding.

This achievement reflects the dedication of countless patients, supporters🙏@MorieGertz, investigators, research staff, industry partners, and advocates who believed in this program over many years. It is also a powerful reminder of why we do translational research-to transform promising science into therapies that meaningfully improve patients' lives.

#ASCO2026 #ALAmyloidosis @Amyloidosis_ARC @Amyloidosisfdn @AmyloidosisSupp @ISA_Amyloidosis

[Matthew Cortese, MD, MPH @Matt_Cortese]

frontMIND just published after great/streamlined presentation by Dr. Lenz et al showing a 2nd PhIII confirmed PFS over R-CHOP (after POLARIX) and appears as an impressive new/upcoming SOC option in #DLBCL #lymsm #ASCO26 @Incyte https://t.co/FJLu11TER9

[Naval Daver, M.D. @Daver_Leukemia]

Thank you @UTMDAnderson . Great to see this important FDA approval for rare cancers the day before ASCO! Truly honored to lead this study with @doctorpemm . Appreciate the tremendous global
collaborators who made it possible!@garciamanero @pistes @ACKoongMDPhD @ChrisRFlowersMD

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

Given the changes in treatment paradigm for myeloma patients, ASCO guidelines are now updated frequently to catch up for the developments

Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1 | 👇@JCO_ASCO @ASCO #mmsm

https://t.co/yuOXCy5f3z

@bdermanmd @RahulBanerjeeMD @LisaHicksMD @HiraSMian @szusmani @MyelomaTeacher @ZanwarSaurabh @myelomaMD @utswcancer